GlassScriptPhysician profile
April Oliver
NPI 1689283293
$872.67
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $258 · 2023: $110 · 2024: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $156.96 | 2021-2024 | Airsupra |
| Abbvie INC. | $121.83 | 2021-2023 | |
| Glaxosmithkline, LLC. | $76.37 | 2021-2023 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $75.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $61.96 | 2024 | |
| Amgen INC. | $58.16 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.05 | 2021 | |
| Lilly USA, LLC | $43.66 | 2022-2024 | Zepbound, Jardiance |
| Pfizer INC. | $36.22 | 2023-2024 | |
| Dexcom, INC. | $22.60 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $22.05 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.66 | 2023 | Rexulti |
| Edwards Lifesciences Corporation | $18.97 | 2024 | |
| Astellas Pharma US INC | $18.66 | 2021 | |
| Novo Nordisk INC | $17.81 | 2023 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2022 | |
| Merck Sharp & Dohme LLC | $17.09 | 2022 | |
| Genentech USA, INC. | $14.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.43 | 2022 | |
| Currax Pharmaceuticals LLC | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.